Exercise Program for Chronic Kidney Disease
(ESTEEM-VIDA Trial)
Trial Summary
What is the purpose of this trial?
Skeletal muscle dysfunction (sarcopenia) is an under-recognized target organ complication of CKD with substantial adverse clinical consequences of disability, hospitalization, and death. Sarcopenia in this proposal is defined by impaired metabolism and physical function associated with decreased skeletal muscle mass or function. Skeletal muscle tissue relies on mitochondria to efficiently utilize oxygen to generate ATP. Impaired mitochondrial energetics is a central mechanism of sarcopenia in CKD. The investigators propose a series of studies designed to shed light on the pathophysiology of sarcopenia in persons with CKD not treated with dialysis. Investigators will conduct a randomized-controlled intervention trial of combined resistance training and aerobic exercise vs. health education to assess changes in skeletal muscle mitochondrial function, metabolism and physical function. Investigators hypothesize that exercise improves mitochondrial function and physical function in persons with CKD. If successful, these experiments will identify novel pathophysiologic mechanisms for CKD-associated sarcopenia. The proposed study will provide useful insight into benefits associated with exercise among patients with CKD and investigate mechanisms associated with improved metabolism, muscle function and physical function in population.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications that affect mitochondrial function, such as muscle relaxants, oral steroids, some antiviral medications, oral calcineurin inhibitors, antiepileptic drugs, antipsychotics, anticoagulants, and antiplatelets. If you are on any of these, you may need to stop them to participate.
What data supports the effectiveness of the treatment Combined Aerobic and Resistance Exercise via videoconferencing for Chronic Kidney Disease?
Research shows that exercise programs, including combined aerobic and resistance exercises, can improve physical function and quality of life in patients with chronic kidney disease. Studies have found that such exercise can enhance aerobic capacity and muscle strength, which are important for overall health and well-being.12345
Is the exercise program safe for people with chronic kidney disease?
How does the treatment of combined aerobic and resistance exercise via videoconferencing differ from other treatments for chronic kidney disease?
This treatment is unique because it combines aerobic (heart and lung fitness) and resistance (muscle strength) exercises that can be done at home through videoconferencing, making it more accessible and convenient for patients with chronic kidney disease compared to traditional in-person exercise programs.2491011
Research Team
Baback Roshanravan, MD MS MSPH
Principal Investigator
UC Davis
Javier Lopez, MD
Principal Investigator
UC Davis Department of Medicine/Division of Cardiology
Eligibility Criteria
This trial is for adults aged 30-75 with moderate to severe chronic kidney disease (CKD) who are not on dialysis and lead a sedentary lifestyle. They must have an eGFR <60ml/min per 1.73m2, not be taking certain medications that affect mitochondria or blood clotting, and cannot have serious heart conditions or other health issues that would make exercise unsafe.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo combined resistance and aerobic exercise supervised by trainers 3 days per week for 12 weeks via videoconferencing, alternating with self-directed sessions.
Follow-up
Participants are monitored for changes in skeletal muscle mitochondrial function, metabolism, and physical function.
Treatment Details
Interventions
- Combined Aerobic and Resistance Exercise via videoconferencing
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Davis
Lead Sponsor